与吲哚美辛治疗动脉导管未闭失败有关。
is associated with indomethacin treatment failure for patent ductus arteriosus.
机构信息
Vanderbilt University School of Medicine, UCSF, Nashville, TN 37232, USA.
Department of Pediatrics, Vanderbilt University Medical Center, UCSF, Nashville, TN 37232, USA.
出版信息
Pharmacogenomics. 2019 Aug;20(13):939-946. doi: 10.2217/pgs-2019-0079.
To identify clinical andgenetic factors associated with indomethacin treatment failure in preterm neonates with patent ductus arteriosus (PDA). This is a multicenter cohort study of 144 preterm infants (22-32 weeks gestational age) at three centers who received at least one treatment course of indomethacin for PDA. Indomethacin failure was defined as requiring subsequent surgical intervention. In multivariate analysis, gestational age (AOR 0.76, 95% CI 0.60-0.96), surfactant use (AOR 9.77, 95% CI 1.15-83.26), and (AOR 3.74; 95% CI 1.34-10.44) were each associated with indomethacin failure. Age, surfactant use, and influence indomethacin treatment outcome in preterm infants with PDA. This combination of clinical and genetic factors may facilitate targeted indomethacin use for PDA.
目的
确定与早产儿动脉导管未闭（PDA）接受吲哚美辛治疗失败相关的临床和遗传因素。 这是一项在三个中心进行的 144 例早产儿（胎龄 22-32 周）的多中心队列研究，这些早产儿接受了至少一个疗程的吲哚美辛治疗 PDA。吲哚美辛治疗失败定义为需要后续手术干预。 在多变量分析中，胎龄（AOR 0.76，95%CI 0.60-0.96）、表面活性剂使用（AOR 9.77，95%CI 1.15-83.26）和（AOR 3.74；95%CI 1.34-10.44）均与吲哚美辛治疗失败相关。 年龄、表面活性剂使用和基因型均影响早产儿 PDA 中吲哚美辛的治疗效果。这些临床和遗传因素的组合可能有助于针对 PDA 进行有针对性的吲哚美辛治疗。
Zotero 插件